Basel, July 18, 2018 – Novartis today announced a new approval for Kisqali (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced…Original Article
Kisqali (ribociclib) Approved for Additional Indications in HR+/HER2- Advanced Breast Cancer
